Entities / Company
Merck KGaA.
German multinational science and technology company
- Reports this week
- 6
- Active events
- 6
- Connections
- 647
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Some support1 report
-
Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.Some support5 reports
-
A combination drug from Merck KGaA and Inhibrx Biosciences showed a higher response rate, leading to a stock price drop reported by Reuters.Some support1 report
-
Merck KGaA announced a definitive agreement to acquire Bio-Techne.Well supported6 reports
-
Merck KGaA is the subject of analyst rating upgrades from HSBC and Scotiabank, alongside increased stock holdings by Geode Capital Management and related SEC filings.Some support1 report
-
Merck KGaA won an award for sustainable innovation.Some support1 report
Earlier this month
-
Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.Some support2 reports1 development inside
-
Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.Some support3 reports
-
Merck KGaA and AstraZeneca's drug pipelines are facing market competition, with J.P. Morgan reiterating an Overweight rating.Some support1 report
-
Robert Plenge holds various appointments, including Chief Research Officer at Bristol-Myers Squibb, and serves on the boards of BioMarin Pharmaceutical and the PhRMA Foundation.Some support1 report
-
Multiple financial institutions, including Norges Bank, Morgan Stanley, and Geode Capital Management, adjusted their holdings in Merck KGaA shares.Some support2 reports
-
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Well supported18 reports10 developments inside
-
Merck KGaA's headquarters are located in Darmstadt, Germany.Some support1 report1 development inside
-
Pfizer, BioNTech, Merck KGaA, and Moderna announced joint developments regarding Comirnaty and a new cancer treatment.Some support1 report
-
Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.Some support2 reports1 development inside
One to three months ago
-
Merck KGaA operates as a science and technology company in Germany.Well supported9 reports1 development inside
-
Norges Bank acquired a new stake in Merck KGaA worth $3.9 billion, filing the required Form 13F with the SEC.Some support4 reports1 development inside
-
Merck KGaA stock saw activity as an EVP sold shares, while Mirae Asset increased its stake, alongside Norges Bank's previous acquisition.Some support1 report
-
MarketBeat is reporting on the company performance of Merck KGaA, a science company based in Germany.Some support1 report
-
Aspen Pharmacare gained rights to manufacture medicines with Merck/MSD to improve access to pharmaceuticals in Africa.Some support2 reports2 developments inside
-
Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.Some support2 reports2 developments inside
-
Pfizer and Merck KGaA are navigating market pressures as the COVID franchise revenue streams decline.Some support1 report
-
Merck KGaA, Gilead Sciences, and Pfizer are competing in the fragmented HIV drug market.Some support1 report
-
A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.Some support1 report1 development inside
-
Merck KGaA filed required documentation with the Securities and Exchange Commission regarding public company oversight.Well supported9 reports1 development inside
-
Morgan Stanley boosted its position in Merck KGaA, while Geode Capital Management lifted its holdings in the company.Some support1 report
-
Merck KGaA received a reaffirmed neutral rating, reduced its stake by 18.5%, and filed 13F reports with the SEC.Some support1 report
-
Litigation in Europe and ongoing FDA review are impacting the market viability and stock performance of Merck KGaA and SamChunDang Pharm.Some support1 report
-
An analyst report was released on July 4, 2026, leading to a target price increase for Merck KGaA.Some support6 reports
-
Merck KGaA and Eli Lilly and Company experienced stock declines on July 20, 2026, amid market sentiment shifts.Some support1 report
-
Merck KGaA and Physiomics plc are providing modeling and data science services.Some support1 report
-
Institutional investors, including Sumitomo Mitsui Trust Holdings, Inc., decreased their holdings in Merck KGaA by 10.1% in Q1 2026.Some support1 report
-
Multiple financial firms, including Citigroup, Bank of America, and Cantor Fitzgerald, issued rating updates on Merck KGaA shares.Some support7 reports
-
Glocer has been appointed to the board of directors at both Merck KGaA and Morgan Stanley.Some support2 reports
Gone quiet
No new reports in 90+ days-
Merck KGaA received analyst coverage and increased institutional stake in its stock from various firms.Some support1 report1 development inside
-
Jefferies Financial Group started coverage on Merck KGaA shares.Some support1 report
-
Roy Vagelos, co-founder of Regeneron, has joined Merck KGaA, rising from R&D to COO.Some support1 report
-
Merck KGaA agreed to acquire Bio-Techne, while an analyst boosted the price target for Avantor stock.Some support1 report
-
Merck KGaA announced a new CEO who previously gained experience at the company.Some support1 report
-
Merck KGaA and Hoffmann-La Roche are seeking FDA approval for combination treatments and expanding pneumococcal vaccine labels.Some support1 report
-
Morgan Stanley bought shares of Merck KGaA on June 16, 2026.Some support1 report
-
Keytruda received FDA approval for cancer treatment, involving Merck KGaA.Some support3 reports
-
Merck KGaA has acquired Terns Pharmaceuticals in a deal valued at $6.7 billion.Some support1 report
-
Geode Capital Management increased its stake in Merck KGaA by 0.4%, purchasing a new stake valued at approximately $3.99 billion.Some support2 reports
-
Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.Some support1 report
-
The FDA is currently evaluating data needed for alternate dosing licenses, while sales in China declined significantly in 2025.Speculative2 reports
-
Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.Some support3 reports
-
Merck & Co. is based in Kenilworth, NJ.Some support1 report
-
Hengrui has formed broad partnerships and licensing deals with Merck & Co., GSK, and Merck KGaA regarding advanced heart disease drugs for hypertrophic cardiomyopathy.Some support1 report
-
Merck & Co.'s board of directors declared financial actions regarding shareholder returns on May 26, 2026.Some support1 report
-
Merck & Co. is based in Rahway, N.J., USA.Some support1 report
-
Merck & Co. and Hengrui Pharma outperformed the S&P 500 in recent stock returns and paid upfront license agreement charges on August 28, 2025.Some support1 report
-
IO Biotech compared its vaccine to Merck & Co.'s Keytruda.Some support1 report
-
Merck & Co. and Avista are appealing to income-focused investors.Some support1 report
-
Merck & Co., GEA Group, and DeLaval are driving global innovations across biopharma, process technology, and dairy farming.Some support1 report
-
Immutep and Merck are combining their therapies, with presentations made at WCLC in Barcelona and engagements held in Paris and Chicago.Some support1 report
-
The market is currently dominated by key players, including Merck & Co., Amgen, and Moderna.Speculative1 report
-
Merck & Co. received FDA approval for Doravirine and is conducting clinical studies in Kenya, South Africa, and Uganda, supported by the Gates Foundation.Some support1 report
-
The FDA is involved as Merck starts trials for a cystic fibrosis medicine developed with Vertex, leading to drug access agreements in Denmark and Ireland.Some support1 report
-
Merck acquired Verona Pharma for $10 billion on August 5, 2025.Well supported11 reports
No events began in the chosen period. Widen it, or reset.
Around Merck KGaA this week
News at the entities that move Merck KGaA most-
Moderna OperationalAnalyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Moves Merck KGaA
-
FDA OperationalGeneric medicine services are seeking approval for launch from the FDA.Moves Merck KGaA
-
Norges Bank TransactionalNorges Bank bought a new position in Qualcomm shares, coinciding with buy ratings and price targets from TD Cowen, reported by MarketBeat.Moves Merck KGaA
-
MSD StructuralMSD and Aurobindo Pharma signed a voluntary licensing agreement for generic alimatravir.Moves Merck KGaA
-
Eli Lilly and Company OperationalExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves Merck KGaA
-
Morgan Stanley StructuralFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Merck KGaA
Connections
The 40 strongest of 647, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
E. Merck Structural
Merck KGaA's related entity was established as a subsidiary of E. Merck.
-
Bio-Techne Transactional
Merck KGaA is acquiring Bio-Techne through a definitive shareholder sale agreement.
-
Moderna Operational
Merck KGaA and Moderna maintain a strategic partnership focused on jointly developing and testing personalized mRNA cancer vaccines.
-
Dean Y. Li Structural
Dean Y. Li serves in an executive capacity at Merck Research Laboratories.
-
FDA Operational
The FDA evaluates and approves pharmaceutical products submitted by Merck KGaA, granting market access based on rigorous review processes.
-
Norges Bank Transactional
Norges Bank acquired a new stake in Merck KGaA valued at approximately $3.9 billion.
-
Securities and Exchange Commission Structural
Merck KGaA operates under the formal regulatory oversight of the SEC, specifically regarding mandatory institutional holdings reports (Form 13F).
-
MSD Structural
MSD operates as a subsidiary of Merck & Co., Inc., utilizing different names based on geographic market.
Show all 40 connections
-
Eli Lilly and Company Operational
The two pharmaceutical companies are direct competitors in the advanced drug development market.
-
Morgan Stanley Structural
The relationship is structural, maintained through shared board representation and active investment/rating coverage by Morgan Stanley.
-
SEC Structural
Merck KGaA is subject to mandatory institutional holdings and investment activity disclosure requirements enforced by the SEC.
-
China Structural
Merck KGaA conducts business operations, including product sourcing and sales, within the Chinese market.
-
Merck Animal Health Structural
Merck Animal Health operates as a dedicated division of the larger entity, Merck KGaA.
-
Pfizer Operational
The companies actively compete in various therapeutic markets, collaborate on specific product approvals, and have engaged in corporate transactions.
-
Veeva Systems Structural
Veeva provides specialized Agentic CRM and AI tools essential for Merck KGaA's ongoing operational functions.
-
Ligand Pharmaceuticals Operational
Ligand Pharmaceuticals and Merck KGaA maintain ongoing partnerships and alliances for drug development.
-
Belén Garijo Structural
Belén Garijo holds the position of CEO at Merck KGaA.
-
Royal Bank of Canada Transactional
RBC issues and reaffirms favorable financial ratings and increases institutional stakes in Merck KGaA stock, culminating in a recent downgrade.
-
Kenneth Frazier Transactional
A served as the leader of B, a role held until 2021.
-
HSBC Mentioned together
HSBC provides financial research reports and target price analysis on Merck KGaA stock.
-
Gilead Sciences Operational
The two companies are current competitors in the fragmented HIV drug market and share a history of collaboration.
-
Bank of America Mentioned together
Bank of America provides financial analysis, raising price targets and issuing buy ratings for Merck KGaA.
-
Oncolytics Biotech Operational
Oncolytics Biotech and Merck KGaA are engaged in a co-development agreement for the drug pelareorep.
-
AstraZeneca Operational
The two companies actively compete against each other within the global pharmaceutical market.
-
Daiwa Securities Operational
The relationship is characterized by market coverage and analyst influence, where upgrades impact market sentiment.
-
Danaher Corporation Operational
The two companies are active competitors operating within the diagnostic market space.
-
Hilltop Holdings Inc. Transactional
Merck KGaA reduced its investment stake in Hilltop Holdings Inc. by 18.5% during Q1.
-
Bioinvent Operational
Both companies are actively competing in the development of novel anti-TNFR2 antibodies.
-
Geode Capital Management Transactional
Geode Capital Management is divesting its stake in Merck KGaA following an initial increase during the fourth quarter of 2026.
-
Severino Structural
Severino held a past executive position within Merck KGaA.
-
Scotiabank Mentioned together
Scotiabank provides financial analysis and price target updates regarding Merck KGaA stock.
-
AbbVie Operational
AbbVie and Merck KGaA are active competitors in the pharmaceutical development and sales market.
-
Cantor Fitzgerald Mentioned together
Both Merck KGaA and Cantor Fitzgerald were mentioned in financial reports regarding ratings and price targets.
-
Wells Fargo Mentioned together
Wells Fargo analysts provided price target updates regarding Merck KGaA stock.
-
Citigroup Mentioned together
The relationship is based on co-mention in financial media, specifically through shared analyst coverage and ratings.
-
MarketBeat Mentioned together
MarketBeat tracks and reports financial data, ratings, and performance summaries for Merck KGaA.
-
Europe Shared context
Merck KGaA operates, serves customers, and seeks to bring benefits to the market within the geographical and regulatory context of Europe.
-
Leerink partners Mentioned together
Leerink partners raised the price target and rating for Merck KGaA in financial coverage.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provides analyst coverage and ratings for Merck KGaA shares.
-
Darmstadt Shared context
Merck KGaA operates from its corporate headquarters located in the city of Darmstadt.
History
Events by the month they beganSeptember 2026
9 events- MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.
- A combination drug from Merck KGaA and Inhibrx Biosciences showed a higher response rate, leading to a stock price drop reported by Reuters.
- Merck KGaA is the subject of analyst rating upgrades from HSBC and Scotiabank, alongside increased stock holdings by Geode Capital Management and related SEC filings.
- Merck KGaA won an award for sustainable innovation.
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
- Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.
- Merck KGaA and AstraZeneca's drug pipelines are facing market competition, with J.P. Morgan reiterating an Overweight rating.
- Robert Plenge holds various appointments, including Chief Research Officer at Bristol-Myers Squibb, and serves on the boards of BioMarin Pharmaceutical and the PhRMA Foundation.
- Pfizer, BioNTech, Merck KGaA, and Moderna announced joint developments regarding Comirnaty and a new cancer treatment.
August 2026
7 events- Multiple financial institutions, including Norges Bank, Morgan Stanley, and Geode Capital Management, adjusted their holdings in Merck KGaA shares.
- Merck KGaA's headquarters are located in Darmstadt, Germany.
- Norges Bank acquired a new stake in Merck KGaA worth $3.9 billion, filing the required Form 13F with the SEC.
- Merck KGaA stock saw activity as an EVP sold shares, while Mirae Asset increased its stake, alongside Norges Bank's previous acquisition.
- MarketBeat is reporting on the company performance of Merck KGaA, a science company based in Germany.
- Pfizer and Merck KGaA are navigating market pressures as the COVID franchise revenue streams decline.
- Merck KGaA, Gilead Sciences, and Pfizer are competing in the fragmented HIV drug market.
July 2026
10 events- Aspen Pharmacare gained rights to manufacture medicines with Merck/MSD to improve access to pharmaceuticals in Africa.
- A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.
- Morgan Stanley boosted its position in Merck KGaA, while Geode Capital Management lifted its holdings in the company.
- Merck KGaA received a reaffirmed neutral rating, reduced its stake by 18.5%, and filed 13F reports with the SEC.
- Litigation in Europe and ongoing FDA review are impacting the market viability and stock performance of Merck KGaA and SamChunDang Pharm.
- An analyst report was released on July 4, 2026, leading to a target price increase for Merck KGaA.
- Merck KGaA and Eli Lilly and Company experienced stock declines on July 20, 2026, amid market sentiment shifts.
- Merck KGaA and Physiomics plc are providing modeling and data science services.
- Institutional investors, including Sumitomo Mitsui Trust Holdings, Inc., decreased their holdings in Merck KGaA by 10.1% in Q1 2026.
- Multiple financial firms, including Citigroup, Bank of America, and Cantor Fitzgerald, issued rating updates on Merck KGaA shares.
Show 1 earlier month
June 2026
34 events- Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.
- Merck KGaA announced a definitive agreement to acquire Bio-Techne.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.
- Merck KGaA operates as a science and technology company in Germany.
- Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.
- Merck KGaA filed required documentation with the Securities and Exchange Commission regarding public company oversight.
- Glocer has been appointed to the board of directors at both Merck KGaA and Morgan Stanley.
- Merck KGaA received analyst coverage and increased institutional stake in its stock from various firms.
- Jefferies Financial Group started coverage on Merck KGaA shares.
- Roy Vagelos, co-founder of Regeneron, has joined Merck KGaA, rising from R&D to COO.
- Merck KGaA agreed to acquire Bio-Techne, while an analyst boosted the price target for Avantor stock.
- Merck KGaA announced a new CEO who previously gained experience at the company.
- Merck KGaA and Hoffmann-La Roche are seeking FDA approval for combination treatments and expanding pneumococcal vaccine labels.
- Morgan Stanley bought shares of Merck KGaA on June 16, 2026.
- Keytruda received FDA approval for cancer treatment, involving Merck KGaA.
- Merck KGaA has acquired Terns Pharmaceuticals in a deal valued at $6.7 billion.
- Geode Capital Management increased its stake in Merck KGaA by 0.4%, purchasing a new stake valued at approximately $3.99 billion.
- Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.
- The FDA is currently evaluating data needed for alternate dosing licenses, while sales in China declined significantly in 2025.
- Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.
- Merck & Co. is based in Kenilworth, NJ.
- Hengrui has formed broad partnerships and licensing deals with Merck & Co., GSK, and Merck KGaA regarding advanced heart disease drugs for hypertrophic cardiomyopathy.
- Merck & Co.'s board of directors declared financial actions regarding shareholder returns on May 26, 2026.
- Merck & Co. is based in Rahway, N.J., USA.
- Merck & Co. and Hengrui Pharma outperformed the S&P 500 in recent stock returns and paid upfront license agreement charges on August 28, 2025.
- IO Biotech compared its vaccine to Merck & Co.'s Keytruda.
- Merck & Co. and Avista are appealing to income-focused investors.
- Merck & Co., GEA Group, and DeLaval are driving global innovations across biopharma, process technology, and dairy farming.
- Immutep and Merck are combining their therapies, with presentations made at WCLC in Barcelona and engagements held in Paris and Chicago.
- The market is currently dominated by key players, including Merck & Co., Amgen, and Moderna.
- Merck & Co. received FDA approval for Doravirine and is conducting clinical studies in Kenya, South Africa, and Uganda, supported by the Gates Foundation.
- The FDA is involved as Merck starts trials for a cystic fibrosis medicine developed with Vertex, leading to drug access agreements in Denmark and Ireland.
- Merck acquired Verona Pharma for $10 billion on August 5, 2025.